Post Analytic Treatment Interruption Study
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Safety and Virologic Outcomes After Analytic Treatment Interruption in Thai Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection|
- Antiretroviral therapy (ART) resumption for any reason [ Time Frame: 96 weeks ]
- Viral suppression after ART resumption [ Time Frame: 48 weeks ]
- Time to viral rebound, from cessation of ART [ Time Frame: 96 weeks ]
- Level of viral rebound after cessation of ART [ Time Frame: 96 weeks ]
- Detectable HIV RNA via single copy assay at various timepoints, such as weeks 48 and 96 off ART, as compared to baseline prior to ATI [ Time Frame: 48 and 96 weeks ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2016|
|Estimated Study Completion Date:||June 2020|
|Estimated Primary Completion Date:||March 2020 (Final data collection date for primary outcome measure)|
|volunteer who completion of a recent ATI|
This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring. Participants without any indication for resumption of ART and who desire to remain off ART at the time of entry into this study will be monitored closely for HIV viremia and other pre-defined criteria for ART resumption. Participants with any indication for ART at the time of enrollment into this protocol, including patient preference for resumption of ART, will be monitored closely for virologic and immunologic response to ART.
Clinical study visits will take place at the Thai Red Cross AIDS Research Centre, and the optional procedures may occur at the King Chulalongkorn Memorial Hospital. Required laboratory studies that are outlined in this protocol will occur in lieu of those described in the RV 254 protocol. Volunteers may provide separate informed consent for optional procedures to include collection of genital secretions, colon biopsy, inguinal lymph node biopsy, cerebrospinal fluid (CSF) collection via lumbar puncture, and brain Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS)/Diffusion Tensor Imaging (DTI). With separate informed consent, willing participants will undergo archival of peripheral blood mononuclear cells and plasma specimens for research purposes.
This study will enroll volunteers aged 18 years and older who have completed clinical studies that include ATI in Bangkok, Thailand. Enrollment in this study will be concurrent with completion of the study with ATI. Participants will fall broadly into one of two categories: those on ART and those not on ART at the completion of the prior study protocol.
The ongoing parent study, RV 254 (SEARCH 010, WRAIR 1494), enrolls participants with documented acute HIV infection at the Thai Red Cross AIDS Research Center in Bangkok, Thailand. Participants in the cohort are primarily men who have sex with men, but also include men and women with other HIV acquisition risk factors as well as various ages, incomes, and education levels. All participants in RV 254 are offered ART at the time of enrollment through a separately funded protocol. Participants in this substudy will remain co-enrolled in RV254/SEARCH010, but will follow the schedule of event (SOE) for this sub-study in lieu of the parent study SOE.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02761200
|Bangkok, Thailand, 10330|
|Principal Investigator:||Nittaya - Phanuphak, MD, PhD||South East Asia Research Collaboration with Hawaii|